Better Cannabis Stock: Canopy Growth vs. Aphria
The U.S. cannabis industry is performing exceptionally well this year, even with a market that's limited by the lack of federal legalization. The coronavirus pandemic has helped drive sales of marijuana, and the drug is seeing growing acceptance as a consumer staple.
However, the case is different in Canada, where marijuana has been legal for awhile now. For several reasons -- including regulatory delays that held up the opening of legal stores and a thriving black market -- Canadian pot companies haven't seen the drastic revenue growth numbers many predicted.
Take Canopy Growth (NYSE: CGC), which is one of the most popular Canadian cannabis stocks, especially after the deal it struck with beverage giant Constellation Brands in 2017. It's also the one with the highest market cap at $6 billion -- but it has yet to hit profitability. Then there's Ontario-based Aphria (NASDAQ: APHA), valued at $1.3 billion and perhaps the only truly safe cannabis stock right now. Let's take a look at which of these two is a better buy.
Source Fool.com
